




S0960-894X(96)00017-0

L-162,389: A POTENT ORALLY ACTIVE ANGIOTENSIN II RECEPTOR ANTAGONIST WITH BALANCED AFFINITY TO BOTH AT₁ AND AT₂ RECEPTOR SUBTYPES.

R. A. Rivero*, N.J. Kevin, S. D. Kivlighn, G. J. Zingaro, R. S. Chang, and W. J. Greenlee

Department of Exploratory Chemistry
Merck Research Laboratories
R50G-331, P.O. Box 2000, Rahway, New Jersey 07065 USA

Abstract: Simple modifications made to our potent angiotensin II AT₁ selective clinical candidate MK-996 provided a compound with balanced binding affinity to both the AT₁ and the AT₂ receptor subtype. This compound, L-162,389, is orally active in rats and dogs.

**Introduction:**


Angiotensin II, the key hormone in the renin-angiotensin cascade, plays a critical role in the regulation of blood pressure and the maintenance of electrolyte balance.¹ The remarkable success achieved by angiotensin converting enzyme inhibitors for the treatment of hypertension and congestive heart failure has generated considerable interest in the development of novel pharmacological agents designed to intervene in the renin-angiotensin system.² During the past several years there have been extraordinary advances in the development of potent AT₁ selective nonpeptide angiotensin II receptor antagonists.³ One such agent, losartan (MK-954), has completed clinical trials and has recently been approved by the FDA.⁴ While no side effects were observed during these trials, it was reported that plasma levels of circulating AII were elevated compared to normal.⁵ It is expected that these elevated levels of AII would have the potential to stimulate AT₂ receptors. Although the functional response to stimulation of the AT₂ receptor is not yet known, we were interested in developing an antagonist which would inhibit the binding of AII to both receptor subtypes. Our strategy was to build AT₂ binding affinity into our potent orally active AT₁ selective antagonist MK-996.⁶ Prior work in our labs had demonstrated that replacement of the benzoylsulfonyl sulfonamide acid group (SO₂NHCOPh) by a *n*-butyl sulfonyl carbamate (SO₂NHCO₂Bu), in a series of quinazolinones, led to analogs with improved AT₂ binding affinity.⁷ We also had previously reported that incorporation of an alkyl group to the 5'-position of the biaryl system increases AT₂ binding affinity in a series of biphenyl triazolinones and phenylthiophene imidazopyridines.⁸ The combination of these two modifications to clinical candidate MK-996 resulted in the discovery of L-162,389 (**1e**), a potent, balanced, and orally active AII antagonist.

Synthesis:

Reaction of *t*-butylamine in dichloromethane with commercially available substituted phenylsulfonyl chlorides (R¹ = H, Me, Et, *n*Pr) cleanly afforded the desired corresponding *t*-butylsulfonamides, **1**. Generation

of the dianion with two equivalents of *n*BuLi in THF at -20° C, followed by quench with trisopropylborate afforded the desired phenylsulfonamide boronic acid derivatives (**2**) in good yield after dilute acid work-up. Suzuki coupling of these boronic acids with the 5,7-dimethyl-3-(4-bromobenzyl)-2-ethylimidazopyridine provided the desired biphenyl analogs (**3**) in 60 to 80% yield.⁹ The *t*-butyl group was then removed with TFA in dichloromethane and the resultant sulfonamide was acylated with an acid chloride or a chloroformate to provide antagonists **I**.¹⁰

SYNTHETIC SCHEME



Results and Discussion:

All final compounds (**I**) competitively blocked the specific binding of the radioligand ¹²⁵I[*Sar*¹,*Ile*⁸]*AlI* to a rabbit aorta (for the AT₁ receptor) and a rat midbrain (for the AT₂ receptor) membrane preparation with IC₅₀'s as listed in the table below.¹¹ A 30-fold increase in the AT₂ binding affinity was observed when the benzoylsulfonamide acid moiety found in MK-996 was replaced by a *n*-butylsulfonyl carbamate group. Addition of a methyl at the 5'-position had little effect on binding affinity at either the AT₁ or the AT₂ receptor. However, addition of an ethyl and finally a propyl group did have a significant impact on binding affinities, compounds **Id** and **Ie**, respectively. This increase in affinity toward the AT₂ receptor was also accompanied by a attenuation of affinity toward the AT₁ receptor in both examples, however the combined binding affinities of **Ie** certainly met the criteria (AT₂/AT₁ IC₅₀ ratios of ≥ 2) set for further development of a balanced antagonist. Compound **Ie** also had good balanced potency in our human receptor assay eliciting IC₅₀'s of 7 nM and 17 nM in the human adrenal AT₁ and AT₂ receptor assay, respectively.¹²

IC₅₀ Binding Affinities

Compound	R ¹	R ²	AT ₁ affinity	AT ₂ affinity
Ia (MK-996)	H	COPh	0.2 nM	2900 nM
Ib	H	CO ₂ <i>n</i> Bu	0.2 nM	95 nM
Ic	Me	CO ₂ <i>n</i> Bu	0.2 nM	87 nM
Id	Et	CO ₂ <i>n</i> Bu	1.4 nM	37 nM
Ie	<i>n</i> Pr	CO ₂ <i>n</i> Bu	2.1 nM	3.8 nM

Compound **Ie**, the 5'-*n*-propyl analog, was further evaluated intravenously and orally in our conscious rat and dog pressor response assay. The results from these experiments are graphically illustrated in Figures 1 and 2, respectively.




Figure 1: A comparison of the duration of action of compound **1e** in conscious rats (open squares) and normotensive dogs (open circles) at 1 mg/kg iv. The pressor responses to AII were measured in each animal after receiving a single dose of **1e**. The animals were challenged with 0.1 μ g/kg of AII at specific time intervals.




Figure 2: A comparison of the duration of action of compound **1e** in conscious rats (closed squares) and normotensive dogs (closed circles) at 3 mg/kg po. The pressor responses to AII were measured in each animal after receiving a single dose of **1e**. The animals were challenged with 0.1 μ g/kg of AII at specific time intervals.

Summary:

We have described alterations to our AT₁ selective clinical candidate MK-996 which provided a potent balanced affinity ligand to both the AT₁ and AT₂ receptors. This balanced antagonist, L-162,389, inhibited the pressor response due to exogenously administered AII in conscious normotensive rats and dogs. At 1

mg/kg i.v in rats L-162,389 showed 85% peak inhibition with a duration of 3 hours. In dogs the same dose resulted in a peak inhibition of 100% with a duration of 4 hours. Orally at 3 mg/kg, a peak inhibition of 70% and 92% was observed with duration of 5-6 hours, in rats and dogs respectively.

Reference and Notes

- (a) Vallotton, M. B. *Trends Pharmacol. Sci.* **1987**, *8*, 69. (b) Johnston, C. I. *Drugs* **1990**, *39*, 21. (c) Waeber, B.; Nussberger, J.; Brunner, H. R. *Handbook of Hypertension*, Vol. 8 Zanchetti, A.; Tarazi, R. C., Eds.; Elsevier: Amsterdam; 1986, pp 489-519. (d) Greenlee, W. J. *Med. Res. Rev.* **1990**, *10*, 173.
- Waeber, B.; Nussberger, J.; Brunner, H. R. *Hypertension: Pathophysiology, Diagnosis and Management*; Laragh, J. H.; Brenner, B. M., Eds.; Raven Press: New York, 1990, pp 2209-2232.
- (a) Carini, D. J.; Duncia, J. V.; Aldrich, P. E.; Johnson, A. L.; Chiu, A. T.; Pierce, M. E.; Price, W. A.; Santella, J. B.; Wells, G. J.; Wexler, R. R.; Wong, P. C.; Yoo, S. E.; Timmermans, P. B. M. W. M. *J. Med. Chem.* **1991**, *34*, 2525. (b) Wong, P. C.; Price, W. A.; Chiu, A. T.; Duncia, J. V.; Carini, D. J.; Wexler, R. R.; Johnson, A. L.; Timmermans, P. B. M. W. M. *J. Pharmacol. Exp. Ther.* **1990**, *255*, 211. (c) Chiu, A. T.; Carini, D. J.; Duncia, J. V.; Leung, K. H.; McCall, D. E.; Price, W. A.; Wong, P. C.; Smith, R. D.; Wexler, R. R.; Timmermans, P. B. M. W. M.; Chang, R. S. L.; Lotti, V. J. *Biochem. Biophys. Res. Com.* **1991**, *177*, 209. (d) Thomas, A. P.; Allott, C. P.; Gibson, K. H.; Major, J. S.; Masek, B. B.; Oldham, A. A.; Ratcliffe, A. H.; Roberts, D. A.; Russell, S. T.; Thomason, D. A. *J. Med. Chem.* **1992**, *35*, 877. (e) Lin, H. S.; Rampersaud, A. A.; Zimmerman, K.; Steinberg, M. I.; Boyd, D. B. *J. Med. Chem.* **1992**, *35*, 2658. (f) Edwards, R. M.; Aiyar, N.; Ohlstein, E. H.; Weidley, E. F.; Griffin, E.; Ezekiel, M.; Keenan, R. M.; Ruffolo, R. R.; Weinstein, J. J. *Pharmacol. Exp. Ther.* **1992**, *260*, 175. (g) Timmermans, P. B. M. W. M.; Wong, P. C.; Chiu, A. T.; Herblin, W. F. *Trends Pharmacol. Sci.* **1991**, *12*, 55. (h) Weinstein, J.; Keenan, R. M.; Samanen, J.; Hempel, J.; Finkelstein, J. A.; Franz, R. G.; Gaitanopoulos, D. E.; Girard, G. R.; Gleason, J. G.; Hill, D. T.; Morgan, T. M.; Peishoff, C. E.; Aiyar, N.; Brooks, D. P.; Fredrickson, T. A.; Ohlstein, E. H.; Ruffolo, R. R.; Stack, E. J.; Sulpizio, A. C.; Weidley, E. F.; Edwards, R. M. *J. Med. Chem.* **1991**, *34*, 1514. (i) Wong, P. C.; Chiu, A. T.; Price, W. A.; Thoolen, M. J. M. C.; Carini, D. J.; Johnson, A. L.; Taber, R. I.; Timmermans, P. B. M. W. M. *J. Pharmacol. Exp. Ther.* **1988**, *247*, 1-7. (j) For a comprehensive review of the patent literature see: Bovy, P. R. and Olins, G. M. *Current Drugs: Renin Angiotensin System*, January, **1992**, B17. (k) For reviews of AT₁-selective antagonists, see: Murray, W. V. *Chemtracts-Orig. Chem.* **1993**, *6*, 263. Buhlmeier, P. *Curr. Opin. Ther. Pat.* **1992**, 1693. Hodges, J. C.; Hamby, J. M.; Blankley, C. J. *Drugs Future* **1992**, *17*, 575.
- Duncia, J. V.; Carini, D. J.; Chiu, A. T.; Johnson, A. L.; Price, W. A.; Wong, P. C.; Wexler, R. R.; Timmermans, P. B. M. W. M. *Med. Res. Rev.* **1992**, *12*, 149.
- Zhang, J.; Entzeroth, M.; Wienen, W.; Van Meel, J. C. A. *European Journal of Pharmacology*, **1992**, *218*, 35.
- Chakravarty, P. K.; Naylor, E. M.; Chen, A.; Chang, R. S. L.; Chen, T.-B.; Faust, K. A.; Lotti, V. J.; Kivlighn, S. D.; Gable, R. A.; Zingaro, G. J.; Schorn, T. W.; Schaffer, L. W.; Broten, T. P.; Siegl, P. K. S.; Patchett, A. A.; Greenlee, W. J. *J. Med. Chem.* **1994**, *37*, 4068.
- Glinka, T. W.; de Laszlo, S. E.; Siegl, P. K. S.; Chang, R. S.; Kivlighn, S. D.; Schorn, T. S.; Faust, K.; Chen, T.-B.; Zingaro, G. J.; Lotti, V. J.; Greenlee, W. J. *Bioorg. & Med. Chem. Lett.* **1994**, *4*, 81-86.
- (a) Chang, L. L.; Ashton, W. T.; Flanagan, K. L.; Rivero, R. A.; Chen, T.-B.; O'Malley, S. S.; Zingaro, G. J.; Kivlighn, S. D.; Siegl, P. K. S.; Lotti, V. J.; Chang, R. S. L.; Greenlee, W. J. *Bioorg. & Med. Chem. Lett.* **1994**, *4*, 2787. (b) Kevin, N. J.; Rivero, R. A.; Greenlee, W. J.; Chang, R. S. L.; Chen, T.-B. *Bioorg. & Med. Chem. Lett.* **1994**, *4*, 189.
- The structure assigned to each new compound is in accord with its mass spectrum (FAB) and high field ¹H NMR (400 MHz).
- Final products were characterized by mass spectrum (FAB), high field ¹H NMR (400 MHz), and combustion analysis (C, H, N; within ± 0.4% of theoretical values).
- For assay details see: (a) Chang, R. S. L.; Siegl, P. K. S.; Clineschmidt, B. V.; Mantlo, N. B.; Chakravarty, P. K.; Greenlee, W. J.; Patchett, A. A.; Lotti, V. J. *Pharmacol. Exp. Ther.* **1992**, *262*, 133. (b) Chang, R. S. L.; Lotti, V. J.; Faust, K. A. *Biochem. Biophys. Res. Commun.* **1990**, *171*, 813.
- Since both AT₁ and AT₂ receptors are present in human adrenal tissues, IC₅₀ values on AT₁ and AT₂ were determined in the presence of 1 μM PD121981 (AT₂ selective ligand) or losartan to prevent binding to the AT₂ and AT₁ receptors, respectively.

(Received in USA 29 September 1995; accepted 27 November 1995)